Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.
Tectal glioma is a midbrain tumor. The patient generally presents with symptoms related to increased intracranial pressure and requires treatment for hydrocephalus. No effective pharmacological treatments have yet been introduced. This report discusses a case of a 13-year-old male diagnosed with tectal glioma who obtained a complete response and long-term survival after the treatment with antineoplastons (ANP) in phase II trial. Prior treatment consisted of placement of a ventriculoperitoneal shunt. After 6 years of stabilization there had been an increase in tumor size with signs of malignant transformation. The patient received treatment with ANP A10 and AS2-1 infusions for 20 months, obtained a complete response, and was switched to maintenance with ANP capsules. All treatments were discontinued in December 2003. Adverse events according to CTCAE v3.0 included: hypernatremia (two events of grade 3, one event of grade 2, four events of grade 1), one case of fatigue (grade 2), and one allergic reaction (grade 1). Currently, over 20 years from his diagnosis and over 13 years from treatment start he is symptom-free and leads a normal life. This report indicates that it is possible to obtain long-term survival of a child with tectal glioma with currently available investigational treatment.
Burzynski Clinic, Houston, Tex., USA.
Stanislaw R
SR
Burzynski
Gregory S
GS
Burzynski
Tomasz J
TJ
Janicki
Ania
A
Marszalek
D000293:Adolescent; D044482:Benzeneacetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004338:Drug Combinations; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy*; D005973:Glutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010648:Phenylacetates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D010881:Piperidones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D016896:Treatment Outcome
D044482:Benzeneacetamides; D004338:Drug Combinations; D010648:Phenylacetates; D010881:Piperidones; D005973:Glutamine; C092038:antineoplaston AS 2-1; C052091:antineoplaston A10